Tat activates human immunodeficiency type 1 gene expression by binding to TAR RNA. TAR comprises a partially base paired stem and hexanucleotide loop with a tripyrimidine bulge in the upper stem. In vitro, Tat binds to the bulge and upper stem, with no requirement for the loop. However, in vivo, loop sequences are critical for activation, implying that a loop binding cellular factor may be involved in the activation pathway.
Given that activation appears to be a two-component system comprising a Tat-bulge interaction and a cellular factor-loop interaction, we considered that it might be possible to spatially separate the two components and retain activation. We have constructed a series of double TAR elements comprising various combinations of mutated TAR structures. Defective TARs with nucleotide substitutions in either the bulge or the loop complemented each other to give wild-type activation. However, the complementation was orientation specific, requiring the intact Tat binding site to reside on the 5'-proximal TAR. These data suggest that provided the wild-type orientation of the bulge and loop elements is retained, there is no requirement for them to coexist on the same TAR structure.
Human immunodeficiency virus type 1 (HIV-1) replication is critically dependent upon the virally encoded Tat protein.
Tat binds to the transactivation response (TAR) element, which is localized between + 14 and +44 at the 5' end of all HIV-1 RNAs (7). TAR is a partially base paired RNA structure comprising a tripyrimidine bulge and an unpaired hexanucleotide loop (10, 23) . The position of TAR relative to the transcription start site is critical for activation, and TAR is functional only when placed in the correct orientation with respect to the HIV-1 long terminal repeat (15, 17, 24, 27) . The predominant mode of action of Tat is to stimulate transcription, and Tat is envisaged as being introduced to the transcription machinery in a feedback process as a protein-bound TAR RNA complex (8) .
In vitro, Tat binds specifically at the bulge, with no requirement for the loop sequence. However, in contrast to the in vitro binding data, mutations in the loop sequence abolish both Tat activation of transcription and translation (4, 5, 11) . This finding implies a requirement for cellular factors to facilitate the binding and/or the activation process. A number of TAR RNA-binding proteins have been identified (12, 14, 19, 22, 25, 29, 37) , some of which bind to the loop sequence, but the function of these cellular factors that bind the loop is controversial. The finding that Tat activates transcription independently of TAR when tethered to RNA via a heterologous RNA-protein interaction (28, 31) or when located upstream of the RNA start in a TAR-less configuration (30) suggests that loop-binding factors cannot be central to the activation pathway. This is consistent with the fact that Tat directly contacts components of the transcription initiation complex (18, 20) . There is, however, some genetic evidence that implies that in the normal TAR configuration, Tat can bind to TAR only when complexed with a loop-binding protein (21) . It has been suggested that the loop-binding protein also mediates the activation. An alternative view is that the loop-binding factors are essential to facilitate access of Tat to the bulge by excluding competing cellular bulge-binding factors (4) .
To investigate further the relationship between the Tatbulge interaction and the cellular factor-loop interaction, we separated the two binding sites by constructing tandem TAR elements downstream of the HIV-1 promoter. The TAR elements were mutated such that they lacked either the Tat binding site at the bulge or the cellular factor loop binding site. The bulge mutation was a substitution of residue U-23 for C-23, and the loop mutation was a three-base substitution of the sequence 30/CUGGG/34 for 30/AGGGU/34. Both of these classes of mutation seriously impair the tat activation process (4, 26) . The general configurations of single and double TAR mutants are shown in Fig. 1 . Single TAR mutants were derived from the wild-type (WT) long terminal repeat-CAT plasmid pOGS210 (1) and retained TAR in the precise WT position but with the base changes indicated (Fig. 1A) . Plasmids containing tandem TAR elements were constructed by inserting a synthetic oligonucleotide, comprising a linker containing an SstII site and residues + 1 to + 62 of TAR as a WT, bulge mutant (BM), or loop mutant (LM) sequence into the unique NheI site of plasmid pOGS210, pPE511, or pPE682. The TAR elements studied were either WT, BM, or LM, and the double TAR elements were combinations of these as indicated in Fig. iC.
To ensure that the analysis was quantitative, we established limiting conditions for Tat activation. The activation of BM and LM TARs in pPE682 and pPE511, respectively, was compared with that of WT (pOGS210) at a range of Tat concentrations provided by expression from plasmid pOGS213 (1) . Plasmids were transfected into subconfluent HeLa cells, and protein extracts were assayed for chloramphenicol acetyltransferase (CAT) activity after 48 h. At a low input of Tat (1 ng of pOGS213), neither the BM nor LM TAR supported activation, whereas WT gave about a 60-fold activation, (Fig. 2) . Consistent with other studies (3, 26) , the mutations were (6) and analyzed by primer extension. Transfection efficiency was determined by cotransfection of human cytomegalovirus promoter-driven luciferase plasmid (pMW41 [35] ), and luciferase assays carried out as described previously (36) . Plasmids encoding WT bulge BM Ti, and LM T2 TAR RNAs (500 ng of each) were transfected into HeLa cells with 0 to 500 ng of pOGS213 and 250 ng of pMW41. Protein extracts containing the same number of luciferase units were assayed for CAT activity.
of TAR elements, we analyzed the activation of tandem WT TARs (DT) and a tandem element in which the first TAR was WT and the second TAR was mutated (T3). The double TAR plasmids were cotransfected with pOGS213 under limiting conditions, and after 48 h, extracts were analyzed for the presence of CAT transcripts and CAT enzyme activity (Fig.  3A) .
Interestingly, the tandem WT TAR gave twice the level of activation of the single TAR (Fig. 3A , lane 4 compared with lane 2). A defective TAR placed downstream of WT had no deleterious effect, as activation levels were the same as obtained with a single TAR (compare lanes 2 and 6). Placing a defective TAR upstream of a WT TAR element also had no effect on activation, whether it was a BM (lane 8) or an LM (lane 10). In these latter configurations, activation levels were the same as obtained with the single TAR (lane 2). These data indicated that a WT TAR element was fully functional whether placed upstream or downstream of a second defective TAR element, indicating that TAR folding and protein interactions were unperturbed by the tandem structure. This finding is also consistent with reports that multiple tandem TAR elements function effectively as TAR decoys (32, 33) . The reason for the increased activation by the tandem WT TARs is not clear, although similar observations were made when HIV-2 TAR elements were duplicated (2) . The finding that a WT TAR can function when placed downstream of a defective element about 90 nucleotides away from the mRNA start appears to be inconsistent with the previously described position dependence of TAR (15, 17, 24, 27) . The result could be explained if the compact secondary structure of the first TAR serves to shorten the distance between the initiation site and the active TAR. Alternatively, an as yet uncharacterized TAR-specific protein Given that tandem HIV-1 TAR elements were functional, we then examined whether different mutated TAR elements could be combined in tandem to allow activation by complementation between the Tat binding site and the loop factor binding site (Fig. 3B) . The combination T4 (BM-LM), which effectively presents a WT loop in the first TAR followed by a WT bulge in the second TAR, showed no activation by Tat (lane 6 (13) . Extracts were assayed after 48 h for CAT activity as described above. RNA was prepared as described previously (6) and analyzed by primer extension. Transfection efficiency was determined as described above.
results with single TAR elements (Fig. 2) . However, the combination T9 (LM-BM), which presents an intact bulge followed by an intact loop, gave activation to the same level as a single WT TAR element (lane 8). These data show that the Tat binding site can function with a loop on a separate TAR element but only in one orientation.
These observations then led us to consider whether this orientation-specific complementation was dependent on close proximity of the two TARs along the length of the transcript. To address this, plasmid constructions T4 and T9 were modified to produce plasmids Ti1 and T10, respectively, by the insertion of a 101-nucleotide oligonucleotide (5'-GGTAA GACACGACTTATCGCCACTGGCAGCAGCCACTGGTA ACAGGATTAGCAGAGCGAGGT'lTGTAGGCGGTGCTA CAGAGTTCTAGAAGTGGTGGCCGC-3') at the unique SstII site, thus spacing the two TAR elements. Plasmid constructions Tll and T10 were tested in a Tat activation assay (Fig. 3C) . As for mutant T4, Tat was unable to activate the TAR configuration in mutant Tll (Fig. 3C, lane 8) . Activation of mutant T10, however, was much reduced compared with the parental construct T9 (compare lanes 2 and 6). Taken together, these data show that while there is surprising flexibility in the relationship of the Tat binding site to the TAR loop, that flexibility does not extend to a separation of 101 nucleotides.
The results are depicted schematically in Fig. 4 . We propose that Tat and the loop-binding protein are asymmetric and that they present interaction surfaces in the WT configuration. In T4, although Tat Fig. 3 If, as proposed previously, Tat must form a stable heterodimer before binding to TAR (21) , then this complex must be able to bridge two TAR elements. Given the in vitro binding properties of Tat (9, 10, 34) , it is perhaps more likely that Tat and the loop-binding factor bind independently but upon contact, facilitated by the flexibility of the RNA, there might be a conformational change in Tat to create an activation surface. The notion of conformational change in Tat is consistent with the finding that isolated activation domains comprising amino acids 1 to 48 bind different proteins from full-length Tat in vitro (16) . It is interesting that separating the bulge and loop on different TAR elements is functional, whereas spacing them by increasing the upper stem results in a nonfunctional TAR (2, 29) . Either there is insufficient flexibility in this latter structure to allow protein interaction or the stretched structure binds a competing factor such as TRBP1 (12) 
